KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Return on Invested Capital (2016 - 2025)

Historic Return on Invested Capital for Travere Therapeutics (TVTX) over the last 12 years, with Q3 2025 value amounting to 1.04%.

  • Travere Therapeutics' Return on Invested Capital rose 123800.0% to 1.04% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.04%, marking a year-over-year increase of 123800.0%. This contributed to the annual value of 1.97% for FY2024, which is 11300.0% up from last year.
  • According to the latest figures from Q3 2025, Travere Therapeutics' Return on Invested Capital is 1.04%, which was up 123800.0% from 1.69% recorded in Q2 2025.
  • Travere Therapeutics' Return on Invested Capital's 5-year high stood at 0.64% during Q2 2021, with a 5-year trough of 13.42% in Q3 2024.
  • Over the past 5 years, Travere Therapeutics' median Return on Invested Capital value was 1.89% (recorded in 2023), while the average stood at 2.84%.
  • Its Return on Invested Capital has fluctuated over the past 5 years, first tumbled by -115300bps in 2024, then surged by 123800bps in 2025.
  • Over the past 5 years, Travere Therapeutics' Return on Invested Capital (Quarter) stood at 0.65% in 2021, then plummeted by -526bps to 4.06% in 2022, then surged by 60bps to 1.62% in 2023, then tumbled by -142bps to 3.91% in 2024, then skyrocketed by 73bps to 1.04% in 2025.
  • Its last three reported values are 1.04% in Q3 2025, 1.69% for Q2 2025, and 1.98% during Q1 2025.